(CercleFinance.com) – The biopharmaceutical company Advicenne announces that ADV7103, its proprietary drug, has obtained orphan drug status (ODD) from the US FDA for the treatment of cystinuria in the United States.
Cystinuria is a genetic disease characterized by an accumulation of the amino acid cystine in the kidneys and bladder, leading to complications that can ultimately lead to chronic kidney failure.
‘The treatment of this condition with simplified alkalinization is an important unmet medical need and constitutes a very significant potential market with more than 30,000 patients in the United States,’ highlights general manager Didier Laurens.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
